IDXX
IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances- 売上
- $4.3bn
- 時価総額
- $45.4bn
株価 $558.80 · 100株 6万円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $3.7bn | $3.9bn | $4.3bn |
| 成長率 | — | 6.5% | 10.4% |
| 総利益 | $2.2bn | $2.4bn | $2.7bn |
| 総利益率 | 59.8% | 61.0% | 61.8% |
| 販管費 | $566m | $589m | $644m |
| 販管費率 | 15.5% | 15.1% | 15.0% |
| 営利 | $1.1bn | $1.1bn | $1.4bn |
| 営利率 | 30.0% | 29.0% | 31.6% |
| 純利益 | $845m | $888m | $1.1bn |
| PBR | 30.6 | 28.5 | 28.3 |
| PSR | 12.4 | 11.7 | 10.6 |
| PGPR | 20.8 | 19.1 | 17.1 |
| PER | 54 | 51 | 43 |
| ﾈｯﾄｷｬｯｼｭ | ▲$244m | ▲$329m | ▲$270m |
| EV/EBITDA | 37.7 | 36.4 | 30.4 |
| Rule of 40 | — | 36% | 42% |
| セールス効率 | — | 842% | 510% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）